Search results
11 gru 2020 · COMIRNATY ® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older; It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:
- View PDF
The Pfizer-BioNTech COVID-19 Vaccine has received EUA from...
- Vaccines Manufacturing B-roll Video
This information—including product information—is intended...
- View PDF
25 cze 2022 · Vaccines. Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron. Saturday, June 25, 2022 - 10:00am. View pdf copy Copy to clipboard Open in tab.
1 wrz 2022 · EMA’s human medicines committee (CHMP) has recommended authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19.
11 wrz 2023 · The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The Pfizer-BioNTech...
22 sie 2024 · COMIRNATY is an FDA-approved vaccine for prevention of COVID-19 in individuals 12 years of age and older that is authorized under EUA to complete the dosing schedule for immunocompromised...
The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years...
4 paź 2021 · EMA’s human medicines committee (CHMP) has concluded that an extra dose of the COVID-19 vaccines Comirnaty (BioNTech/Pfizer) and Spikevax (Moderna) may be given to people with severely weakened immune systems, at least 28 days after their second dose.
